Abstract library

932 results for "targeted therapy".
#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience
Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Nuclear Medicine - Imaging and Therapy (PRRT)
Presenting Author: Dr Sugandha Dureja
Authors: Dureja S, Sen I, Pant V, Thak P
#1404 The Proteasome Inhibitor Bortezomib Is a Highly Effective Treatment Option for Gastroenteropancreatic Neuroendocrine Neoplasms and Sensitizes to DNA Damaging Therapy In Vitro
Introduction: Gastroenteropancreatic neuroendocrine neoplasms are fairly rare tumors with very heterogeneous behavior and molecular characteristics. Their generally slow proliferation render them virtually resistant to many DNA damaging therapeutic approaches. Bortezomib has been shown to be effective in GEP-NENs in vitro but has been withdrawn from clinical assessment due to a small phase II study on bortezomib monotherapy in 2004.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Franziska Briest
#1240 Targeted Therapies as First Line Option in Very Advanced Unresectable Pancreatic Neuroendocrine Tumors
Introduction: Neuroendocrine tumors are an entity of rare, heterogeneous group of tumors that can arise from different sites within the body. Although number of different treatment types and modalities exist, chemotherapy remains as the first line option in the management of advance pancreatic NETS (pNETS); two targeted therapies, sunitinib and everolimus remains available only for second line and beyond in Canada.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: MD Young Soo Rho
Authors: Rho Y S, Gilabert M, McLean J, Kavan P, ...
#1526 Therapeutic Strategies in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NEN): Results from the National Neuroendocrine Cancer Registry of Spain (R-GETNE)
Introduction: The Spanish National Neuroendocrine Cancer Registry is a hospital-based registry of GEP-NENs launched by GETNE in 2001.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Others
Presenting Author: PhD Paula Jimenez-Fonseca
#280 Sorafenib and Bevacizumab Combination Targeted Therapy in Advanced Neuroendocrine Tumor: A Phase II Study of the Spanish Neuroendocrine Tumor Group (GETNE0801)
Introduction: Sorafenib (S) and bevacizumab (B) as single agents have shown efficacy and acceptable toxicity in NETs phase II trials. S+B combination has shown manageable toxicity in phase I trials in solid tumors.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Mrs. Cristina Garrido
#1367 Thymic Neuroendocrine Neoplasia: Therapy with Everolimus
Introduction: Due to the low incidence of 0.02/100 000 no established medical therapy for thymic neuroendocrine neoplasia (t-NEN) exists.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Dr. med. Matthias Lang
Authors: Lang M, Anamaterou C, ...
#1842 OPALINE Study: Observational Study in a Real-World Setting of the Systemic Treatment of Progressive Unresectable or Well-Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET).
Introduction: OPALINE Study focuses on patients with pNET. Two targeted therapies (TT) offer new options to treat these patients: mTORi (everolimus) and a multi-targeted inhibitor (sunitinib).
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Julie Grellier de Heaulme
#1008 STZ-Based Chemotherapy is Associated with Durable Response Rate in Pancreatic NET as 1st or 2nd Line Treatment
Introduction: The role of chemotherapy for pancreatic neuroendocrine tumors (pNETs) is controversially discussed. Objective response rates (RR) with streptozocin (STZ)-based chemotherapy are variable. Novel targeted drugs have recently been approved.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: Lisa-Marie Dilz
#1060 Fifty-Three Year-Old-Male with a Symptomatic Ileocecal Carcinoid: An Individual Follow-Up of 14 Yrs with 5 Different Anti-Proliferative Therapies
Introduction: Only limited reports exist about sequence of different anti-tumor therapies in patients with neuroendocrine tumors (NETs) after primary surgery.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: MD Patrizia Kump
#2974 MEK/RAF and PARP as Novel Targets in Neuroendocrine Neoplasms – First Results from a Molecular in vitro Tumor Board
Introduction: Neuroendocrine neoplasms (NEN) are a heterogeneous group comprising well differentiated neuroendocrine tumors (NET) and poorly differentiated neuroendocrine carcinomas (NEC). Although, major progress has been made in the development of targeted therapies in various cancers, establishment of a promising personalized therapy in NEN is still pending. So far, a lack of suitable preclinical models represent a major challenge concerning the validation of a mutational based targeted therapy (MBTT)
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - In vitro models, tumor growth, CTCs
Presenting Author: Fabrice Viol
Authors: Viol F, Sipos B, Amin T, Fahl M, ...